 IRVINE, Calif., April 29, 2022 GLOBE NEWSWIRE -- Tarsus Pharmaceuticals, Inc. NASDAQ: TARS, whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, will hold a webcast on Monday, May 2, 2022 at 5:00am PT8:00am ET to review the topline results from the Saturn-2 Phase 3 trial for TP-03 lotilaner ophthalmic solution, 0.25 for the treatment of Demodex blepharitis and provide a brief corporate update. 